HR Execs on the Move

I.C.H. Corporation

www.ichcorp.com

 
I.C.H. Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million
  • www.ichcorp.com
  • 9255 Towne Centre Dr Ste 600
    San Diego, CA USA 92121
  • Phone: 858.587.8533

Executives

Name Title Contact Details

Similar Companies

BIOSAFE Inc

BIOSAFE Inc is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Essential Formulas

Essential Formulas is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Fruth Pharmacy

Fruth Pharmacy has been serving Southwestern West Virginia and Southern Ohio Since 1952. We cater to the needs of our customers by providing the best customer service in town. Fruth's pharmacists are on duty 7 days a week and are dedicated to serving

Forma Therapeutics

At FORMA, patients are our purpose. We are dedicated to delivering transformative medicines to patients with cancer and rare diseases. We are a fully-integrated, privately-held clinical stage biopharmaceutical company. A leader in metabolism, epigenetics and protein homeostasis focused on the discovery, development and commercialization of transformative medicines. Our proprietary R&D platform combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates. We have delivered high-value clinical candidates to our partners and generated a broad proprietary portfolio of internal programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic and metabolic indications.

Promentis Pharmaceuticals

Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.